Chromogranin A
Chromogranin A (CgA), a 439-residue long glycoprotein is a secretory protein of the ‘granin’ family. It is present in normal and tumor tissues of neuroendocrine origin. It is a precursor to various functional peptides like vasostatin, pancreastatin, catestatin and parastatin. The N-terminal domain of CgA binds to SgIII receptor at the level of pituitary, pancreatic and neuroendocrine cells. CgA can be present as full length CgA or shorter fragments like Vaostatin-1 (CgA1-76), Vasostatin-2 (CgA1-113), pancreastatin (CgA250-301), catestatin (CgA352-372) or seroinin (CgA411-436). Full length CgA or its fragments are involved in various regulatory functions including vasodilatory effects in different tissues, inhibition of parathyroid hormone, inhibition of insulin secretion, inhibition of catecholamine release, protective effects on neurons, myocardial contractility and counteraction of β adregenic induced positive inotropism. CgA, including its fragments are useful biomarkers in neuroendocrine tumors including carcinoid, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas (MTC), some pituitary tumors, islet cell tumors, and amine precursor uptake and decarboxylation (APUD) tumors. CgA level may also elevated in a number of non-neuroendocrine tumor such as small-cell carcinoma of the lung or prostate carcinoma.
- Aids in the diagnosis and monitoring of carcinoid tumor
- Aids in the diagnosis and monitoring of various tumors arising from neuroendocrine cells
Increased in:
- Neuro-endocrine tumors like carcinoid tumor of stomach, intestine, lungs
- Pheochromocytoma
- Non-neuroendocrine tumor such as small-cell carcinoma of the lung or prostate carcinoma
- Impaired renal function
- Liver disease
- Protein pump inhibitor (PPI) therapy
Less than 100 ng/ml
Serum (SST), Plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen:14 days
Avoid Protein Pump Inhibitor (PPI) therapy for 2 weeks before sample collection.
- N Engl J Med. 1986; 314: 1145-51 [PMID: 3007986]
- Ann Clin Biochem. 2014; 51: 8-21 [PMID: 23939195]
- Clin Chem. 2012; 58: 941-3 [PMID: 22361937]
- Pancreas. 2010; 39: 753-66 [PMID: 20664473]
- J Clin Endocrinol Metab. 2008; 93: 91-5 [PMID: 17940110]
- Bull Exp Biol Med. 2016; 160: 702-4 [PMID: 27021085]
- J Urol. 1997; 157:565-8. [PMID: 8996358]
- Pathol Oncol Res. 2017; 23: 643-650 [PMID: 28012116]